{"nctId":"NCT02635776","briefTitle":"Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)","startDateStruct":{"date":"2015-12-22","type":"ACTUAL"},"conditions":["Peanut Allergy"],"count":555,"armGroups":[{"label":"AR101 powder provided in capsules & sachets","type":"EXPERIMENTAL","interventionNames":["Biological: AR101 powder provided in capsules & sachets"]},{"label":"Placebo powder provided in capsules & sachets","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo powder provided in capsules & sachets"]}],"interventions":[{"name":"AR101 powder provided in capsules & sachets","otherNames":[]},{"name":"Placebo powder provided in capsules & sachets","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Age 4 through 55 years\n* Clinical history of allergy to peanuts or peanut-containing foods\n* Serum immunoglobulin E (IgE) to peanut ≥0.35 kUA/L (kilos of allergen-specific units per liter, determined by UniCAP™\\* within the past 12 months) and/or a skin prick test (SPT) to peanut ≥3 mm compared to control\n* Experience dose-limiting symptoms at or before the 100 mg challenge dose of peanut protein (measured as 200 mg of peanut flour) on Screening DBPCFC conducted in accordance with PRACTALL\\*\\* guidelines\n* Not be residing at the same address as another subject in this or any peanut OIT study\n\nUniCAP™\\*: a laboratory system for routine diagnostic testing of allergy and tool for basic studies on allergens and antibodies\n\nPRACTALL\\*\\*: PRACTical issues in ALLergology Joint United States/European Union Initiative\n\nKey Exclusion Criteria:\n\n* History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension\n* History of severe or life-threatening episode of anaphylaxis or anaphylactic shock within 60 days of Screening DBPCFC\n* History of chronic disease (other than asthma, atopic dermatitis, or allergic rhinitis) that is, or is at significant risk of becoming, unstable or requiring a change in chronic therapeutic regimen\n* History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology\n* History of severe asthma (NHLBI criteria steps 5 or 6), or mild to moderate asthma (2007 NHLBI criteria steps 1-4) that is uncontrolled or difficult to control\n* History of steroid medication use\n* History of a mast cell disorder, including mastocytosis, urticarial pigmentosa, and hereditary or idiopathic angioedema\n* Developing dose-limiting symptoms in reaction to the placebo part of the Screening DBPCFC\n* Having the same place of residence as another subject in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"55 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Ages 4-17 Who Tolerated a Single Highest Dose of at Least 600 mg in the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC)","description":"The percentage of subjects in the ITT population who achieve desensitization as determined by tolerating specified challenge doses of peanut protein with no more than mild symptoms at the Exit Oral Food Challenge.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"250","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Ages 4-17 Who Tolerated a Single Highest Dose of at Least 1000 mg in the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC)","description":"The percentage of subjects in the ITT population who achieve desensitization as determined by tolerating specified challenge doses of peanut protein with no more than mild symptoms at the Exit Oral Food Challenge.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Ages 4-17 Who Tolerated a Single Highest Dose of at Least 300 mg in the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC)","description":"The percentage of subjects in the ITT population who achieve desensitization as determined by tolerating specified challenge doses of peanut protein with no more than mild symptoms at the Exit Oral Food Challenge.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"285","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Ages 4-17 by Maximum Severity of Symptoms Occurring at Any Challenge Dose of Peanut Protein During the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC)","description":"The maximum severity of symptoms on 4 levels: 0-None, 1-Mild, 2-Moderate, 3-Severe or higher (Severe, life threatening, fatal) observed in the DBPCFC at any dose (1000 mg or lower).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"35","spread":null}]},{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"73","spread":null}]},{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":372},"commonTop":["Abdominal pain","Cough","Pruritus","Throat irritation","Abdominal pain upper"]}}}